

Phytohemagglutinin

Cat. No.:	HY-N7038
CAS No.:	9008-97-3
Target:	NF-κB; COX; Interleukin Related; Reactive Oxygen Species (ROS)
Pathway:	NF-κB; Immunology/Inflammation; Metabolic Enzyme/Protease
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Phytohemagglutinin

SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 10 mg/mL (ultrasonic and warming and heat to 60°C)
In Vivo	1. Add each solvent one by one: PBS Solubility: 50 mg/mL (Infinity mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description	Phytohemagglutinin (PHA-M), the major seed lectin of the common bean, <i>Phaseolus vulgaris</i> , is a T-cell activator. Phytohemagglutinin stimulates human mononuclear leukocytes, inducing the expression of ChAT mRNA and potentiating ACh synthesis. Phytohemagglutinin induces dose- and time-dependent toxicity in THP-1 monocytes/macrophages, alters cellular morphology, causes organelle dysfunction, and increases the expression of <i>NF-κB</i> , <i>COX2</i> , <i>IL-1β</i> ^{[1][2][3][4]} .
IC ₅₀ & Target	Apoptosis ^[1]
In Vitro	Phytohemagglutinin (0.1-1000 μg/mL, 24 h) induces a reduction in cell number, the adoption of a rounded morphology, cytoskeletal destabilization and toxic response in THP-1 cells ^[1] . Phytohemagglutinin (0.1-1000 μg/mL, 24-72 h) reduces mitochondrial activity and lysosomal activity in MDM cells, causing significant viability loss at higher concentrations (1000 μg/mL) and prolonged exposure (72 h) ^[1] . Phytohemagglutinin (0.1-1000 μg/mL, 1-72 h) does not significantly induce ROS production in MDM cells at concentrations up to 1000 μg/mL over 72 h, showing only a slight increase in free radicals at 24 h with 1000 μg/mL ^[1] . Phytohemagglutinin (10-1000 μg/mL, 24 h) increases the expression of <i>NF-κB</i> , <i>COX2</i> , <i>IL-1β</i> and decreases the expression of <i>TNF-α</i> in MDM cells ^[1] . Phytohemagglutinin binds to the membranes of T-cells, stimulates metabolic activity, cell division ^[2] . Phytohemagglutinin (5μg/mL, 48 h) stimulates PBMCs to secrete high levels of inflammatory cytokines, including <i>IL-6</i> , <i>TNF-α</i> , <i>IL-1β</i> , <i>IFN-γ</i> , <i>IL-4</i> , <i>IL-2</i> , <i>IL-12</i> , <i>IL-10</i> , and <i>IL-17</i> , while significantly reducing <i>IL-8</i> levels ^[4] . Phytohemagglutinin significantly reduces RGC-32 expression and inhibits the growth of renal cancer cells, an effect reversed by PD-L1 ligation ^[4] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Immunofluorescence ^[1]

Cell Line:	THP-1 cells and MDM cells
Concentration:	0.1, 1, 100, 1000 µg/mL
Incubation Time:	24 h
Result:	Induced a loss of membrane integrity, which in turn led to the detachment of THP-1 cells from the culture flask at 1000 µg/mL. Caused a reduction in cell number as a result of membrane destabilization. Induced lysosomal membrane destabilization and reduction in MDM cell number at 100 and 1000 µg/mL. Reduced mitochondrial membrane potential at 10 and 1000 µg/mL in MDM cells. Elicited significant membrane permeabilization in MDM cells at 1000 µg/mL.

CUSTOMER VALIDATION

- Cancer Commun (Lond). 2024 May 12.
- Drug Resist Updat. 2024 Jun 24;76:101112.
- J Ethnopharmacol. 2022 Jun 12;291:115126.
- Int Immunopharmacol. 2025 Dec 17;169:116039.
- Sci Rep. 2025 Oct 27;15(1):37515.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Prajitha N, et al. Intracellular inflammatory signalling cascades in human monocytic cells on challenge with phytohemagglutinin and 2,4,6-trinitrophenol. Mol Cell Biochem. 2022 Feb;477(2):395-414.
- [2]. Movafagh A, et al. The Significance Application of Indigenous Phytohemagglutinin (PHA) Mitogen on Metaphase and Cell Culture Procedure. Iran J Pharm Res. 2011 Fall;10(4):895-903.
- [3]. Fujii T, et al. Induction of choline acetyltransferase mRNA in human mononuclear leukocytes stimulated by phytohemagglutinin, a T-cell activator. J Neuroimmunol. 1998 Feb;82(1):101-107.
- [4]. Li L, et al. Response Gene to Complement 32 is associated with poor patient survival and an inflamed tumor-immune microenvironment in clear cell renal cell carcinoma. Transl Oncol. 2025 Feb;52:102248.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA